Cholesterol is essential for cells to grow and proliferate. Normal mammalian cells meet their need for cholesterol through its uptake or de novo synthesis 1 , but the extent to which cancer cells rely on each of these pathways remains poorly understood. Here, using a competitive proliferation assay on a pooled collection of DNA-barcoded cell lines, we identify a subset of cancer cells that is auxotrophic for cholesterol and thus highly dependent on its uptake. Through metabolic gene expression analysis, we pinpoint the loss of squalene monooxygenase expression as a cause of cholesterol auxotrophy, particularly in ALK + anaplastic large cell lymphoma (ALCL) cell lines and primary tumours. Squalene monooxygenase catalyses the oxidation of squalene to 2,3-oxidosqualene in the cholesterol synthesis pathway and its loss results in accumulation of the upstream metabolite squalene, which is normally undetectable. In ALK + ALCLs, squalene alters the cellular lipid profile and protects cancer cells from ferroptotic cell death, providing a growth advantage under conditions of oxidative stress and in tumour xenografts. Finally, a CRISPR-based genetic screen identified cholesterol uptake by the low-density lipoprotein receptor as essential for the growth of ALCL cells in culture and as patient-derived xenografts. This work reveals that the cholesterol auxotrophy of ALCLs is a targetable liability and, more broadly, that systematic approaches can be used to identify nutrient dependencies unique to individual cancer types.
DNA barcode (Fig. 1c ). As lipoproteins are the major carriers of cholesterol in human serum 9 , the pooled population of cell lines was cultured in lipoprotein-replete or lipoprotein-depleted medium for three weeks. Of note, the absence of lipoproteins did not affect the proliferation of most cell lines, suggesting that they can obtain sufficient cholesterol through de novo synthesis ( Fig. 1d , Extended Data Fig. 1b , c, Supplementary Table 1 ). However, lipoprotein depletion did strongly reduce the proliferation of a subset of cancer cell lines, not only U-937, but also U266B1, Raji, Jiyoye and SNU-1-cell lines not previously known to be sensitive to lipoprotein depletion ( Fig. 1d, e ). In individual growth assays, these cells can proliferate in lipoprotein-depleted conditions when supplemented with free cholesterol, arguing against an essential role for other components of lipoproteins (Extended Data Fig. 1c, d) . These data demonstrate that strong extracellular cholesterol dependencies can exist in cancer cells of distinct origins.
Cholesterol biosynthesis occurs through a pathway of over thirty successive steps that converts acetyl-CoA to squalene, which is then cyclized into lanosterol and other downstream sterol compounds 1 . Although oncogenic alterations may reprogram cholesterol metabolism in a subset of cancers 10 , the presence or absence of such mutations did not correlate with differences in the sensitivity to cholesterol depletion (Extended Data Fig. 1e ). We therefore considered that a defect in a cholesterol synthesis gene might render these cells auxotrophic for cholesterol. Analysis of transcriptome-wide gene expression data from the Cancer Cell Line Encyclopedia (CCLE) revealed that one of the cholesterol-dependent cell lines, SNU-1, does not express squalene monooxygenase (SQLE) mRNA or SQLE protein ( Fig. 2a , Extended Data Fig. 1f, g) . Consistent with a block in the SQLE-catalysed step of cholesterol biosynthesis, expression of SQLE was sufficient to enable the proliferation of SNU-1 cells under cholesterol-depleted conditions (Fig. 2b, Extended Data Fig. 1h ). SQLE catalyses the conversion of squalene to squalene-2,3-epoxide and is a rate-limiting step in sterol synthesis in mammalian cells 11 (Extended Data Fig. 1i ). Although squalene, the upstream metabolite in this reaction, is undetectable in most cancer and normal cells, lack of SQLE expression results in accumulation of squalene in SNU-1 cells, which further validates the absence of SQLE activity (Fig. 2c) . Thus, the SNU-1 cell line is a bona fide cholesterol auxotroph because of its lack of SQLE activity.
Using gene expression data from the CCLE, we identified nine additional cell lines without detectable SQLE mRNA and SQLE protein. Of note, six of these cell lines (SU-DHL-1, KIJK, SUP-M2, DEL, SR-786 and Karpas299) belong specifically to the cancer subtype ALK + ALCLs (Fig. 2d, e ). Similar to SNU-1, SQLE-deficient ALCL cell lines are sensitive to cholesterol depletion ( Fig. 2f ) and accumulate high amounts of squalene ( Fig. 2g ). Chemical imaging using stimulated Raman scattering (SRS) microscopy further revealed that, whereas control cells lack squalene, ALCLs accumulate it in lipid droplets (Fig. 2h , Extended Data Fig. 2a, b ). Loss of SQLE expression is associated with promoter hypermethylation, and treatment with DNA-hypomethylating agents upregulates SQLE mRNA expression (Extended Data Fig. 2c-e ). We next investigated whether SQLE downregulation is also a feature of primary tumour samples and patient-derived tumour xenografts (PDXs) of ALK + ALCLs. Analysis of previously published mRNA expression data from ALCLs 12 and quantitative PCR of primary tumour samples revealed that SQLE is indeed one of the most significantly differentially expressed genes in primary ALK + ALCL tumours compared to ALK − ALCLs (Fig. 2i , Extended Data Fig. 3a, b , Supplementary  Table 2 ). In agreement with the mRNA data, we observed a marked reduction of SQLE protein levels in primary ALK + ALCL tumours compared to other lymphoma types (Extended Data Fig. 3c-e ). Despite highly significant inverse correlation between NPM-ALK translocation and SQLE expression, modulation of ALK signalling did not affect SQLE expression, which suggests that SQLE may be silenced owing to a different mechanism (Extended Data Fig. 3f-h) . Altogether, these results demonstrate that ALK + ALCLs lack SQLE expression and thus are cholesterol auxotrophs.
Given the strong cholesterol dependency of ALK + ALCLs, we next explored whether this unexpected metabolic feature could be exploited as a therapeutic vulnerability. Using a focused CRISPR library targeting 200 core metabolic enzymes ( Supplementary Table 3 ), we performed a negative selection screen to identify genes the loss of which inhibits the fitness of cholesterol auxotrophic ALK + ALCL cells but not of their SQLE-expressing counterparts or a prototrophic cell line ( Fig. 3a , Extended Data Fig. 4a ). The highest scoring gene in these screens was the low-density lipoprotein (LDL) receptor (LDLR) (Fig. 3b , Extended Data Fig. 4b-d , Supplementary Table 4 ). LDLR provides a major source of cholesterol for mammalian cells by serving as the cell-surface receptor for the endocytosis of cholesterol-rich LDL 1, 9 . Consistent with the screen results and the essential role of LDLR in the survival of ALCLs, depletion of LDLR using a conditional CRISPR-Cas9 system (Fig. 3c , Extended Data Fig. 4e -i) or targeting it with a monoclonal anti-LDLR antibody (Extended Data Fig. 4j -l) strongly decreased the proliferation of ALK + ALCL lines but not of control cells. ALK + ALCLs upregulate LDLR-mediated cholesterol uptake (Extended Data Fig. 5a ) and expression of cholesterol uptake genes ( Fig. 3d , Extended Data Fig. 5b -e) to compensate for their deficiency in de novo cholesterol biosynthesis, an adaptation essential for ALK + ALCL cells to proliferate. Consistent with these findings, CRISPR-Cas9-mediated LDLR depletion inhibited the growth of mouse tumour xenografts derived from ALK + ALCL cancer cell lines (DEL and Karpas299) but not that of a control cell line (KMS-26) ( Fig. 3e ). To translate our findings to a more relevant in vivo model, we asked whether targeting LDLR affects the growth of PDXs. For this, we performed an in vivo loss-of-function competition assay using a pool of single guide RNAs (sgRNAs) targeting control genomic regions or the LDLR gene. The sgRNAs targeting the LDLR gene strongly inhibited the growth of tumours derived from the DEL cell line as well as from three different ALK + ALCL PDXs, but not that of isogenic tumours expressing SQLE ( Fig. 3f ). Collectively, our data identify cholesterol uptake through LDLR as a therapeutic target for ALK + ALCLs in vivo.
We reasoned that a decrease in cholesterol synthesis was unlikely to confer an advantage to cancer cells and so investigated whether loss of SQLE activity might have other beneficial effects on ALCL metabolism and growth. As the accumulation of certain metabolites in cancer cells can promote tumorigenesis by altering cellular processes distinct from the original metabolic pathways in question 4, 6, 13 , we focused our attention on squalene, a relatively poorly characterized metabolic intermediate that accumulates at very high levels upon SQLE loss ( Fig. 2g ). Squalene is a main component of human sebum and is proposed to have a role as an emollient and a natural antioxidant for the skin, but the role of squalene in cancer biology has been poorly explored 14, 15 . To understand the metabolic consequences of squalene accumulation in ALCLs, we genetically targeted squalene synthase (FDFT1), the enzyme immediately upstream of SQLE in cholesterol biosynthesis responsible for the synthesis of squalene. CRISPR-Cas9-mediated knockout of FDFT1 blocked squalene synthesis, and returned squalene to levels seen in non-ALCL cells ( Fig. 4a , b, Extended Data Fig. 6a, b ). To test whether squalene accumulation in ALK + lymphomas is beneficial for tumour formation in vivo, we generated tumours by injecting FDFT1knockout Karpas299 cells expressing a vector or an sgRNA-resistant FDFT1 cDNA subcutaneously into immunodeficient mice. Loss of FDFT1 caused a marked decrease in the size of Karpas299 tumours ( Fig. 4c ). Similarly, competition experiments using FDFT1 and control sgRNAs in two ALK + PDX models showed a significant depletion of FDFT1 sgRNAs (Extended Data Fig. 6c ). These data suggest that squalene synthesis may be beneficial for optimal growth of ALK + ALCLs in vivo.
We next investigated how squalene may affect cellular metabolism in ALK + ALCLs. As accumulation of lipid peroxides are detrimental to cell viability, most mammalian cells repair lipid damage using the phospholipid peroxidase glutathione peroxidase 4 (GPX4), inhibition of which causes ferroptosis, a recently described form of cell death [16] [17] [18] . Squalene is a lipophilic metabolite that can accumulate in cellular membranes and lipid droplets ( Fig. 2h , Extended Data Fig. 2b ). We therefore investigated whether squalene may be protective of lipid peroxidation and ferroptotic cell death. Blocking squalene accumulation by genetic loss of FDFT1 (Fig. 4d , Extended Data Fig. 6d -g) or e, boxes represent the median, and the first and third quartiles, and the whiskers represent the minimum and maximum of all data points. b, n = 3 biologically independent samples; d, n = 3 independent barcodes per cell line; e, n = 5-6 biologically independent cell lines. Statistical significance was determined by two-tailed unpaired t-test. Letter reSeArCH small molecule inhibitors (Extended Data Fig. 7 ) sensitized SQLEdeficient cells to ferroptosis induced by GPX4 inhibitors (ML162 and RSL3). Extracellular squalene supplementation fails to provide this protective phenotype, which suggests that squalene may need to accumulate in the right cellular compartments for its function (Extended Data Fig. 8 ). Consistent with cell death by ferroptosis, the addition of an antioxidant (ferrostatin-1) or blocking long-chain polyunsaturated fatty acid (PUFA) incorporation into membrane lipids by knocking out acyl-CoA synthetase long-chain family member 4 (ACSL4) 19 eliminated the sensitivity of FDFT1-knockout ALCLs to GPX4 inhibitors ( Fig. 4d , Extended Data Fig. 9a-c) . Similarly, expression of SQLE cDNA in ALCL cells decreased squalene levels, sensitized them to GPX4 inhibitors and blunted in vivo tumour growth ( Fig. 4b-d , Extended Data Fig. 6a, d, e ). Additionally, a decrease in squalene levels upon FDFT1 loss or SQLE overexpression increased lipid reactive oxygen, a hallmark of ferroptosis rescued by antioxidants when cells were treated with ferroptosis inducers (Extended Data Fig. 9d, e ). As membrane PUFAs are highly susceptible to damage by oxidation 19 , squalene accumulation may protect these membrane lipids from chemical modification or rewire membrane lipid composition, thereby providing a survival advantage to them under oxidative stress. Reflective of the protective role of squalene, loss of squalene accumulation enhanced the depletion of membrane PUFAs containing arachidonic acid (AA, 20:4), adrenic acid (AdA, 22:4) and docosahexaenoic acid (DHA, 22:6) in FDFT1null cells on ML162 treatment ( Fig. 4e , Extended Data Fig. 10a -c). Although an increase in the levels of GPX4 protein or coenzyme Q 20,21 by inhibition of the lower sterol synthesis pathway can protect against lipid peroxidation (Extended Data Fig. 10d ), we did not observe a change in levels of GPX4 protein or coenzyme Q in ALK + ALCLs on FDFT1 loss (Extended Data Figs. 7, 10e-f). Therefore, our findings reveal that squalene is a lipophilic metabolite that is elevated in ALK + ALCLs and can prevent damage of membrane PUFAs under oxidative stress. Squalene abundance (a.u.)
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Cancer-associated alterations in metabolic enzymes influence the levels of metabolic intermediates and may thereby affect nonmetabolic cellular functions such as signalling and the epigenetic state 5, 13 . For example, succinate and fumarate accumulate in cancers with SDH or FH mutations and may exert their pro-tumorigenic effects by acting as epigenetic modulators 22, 23 . Here we find that ALK + ALCLs lose squalene monooxygenase activity and accumulate squalene, a metabolite with antioxidant-like properties ( Fig. 4f ). As activation of cellular antioxidant defence is selected for in some tumour types 24 or under certain stresses 21, 25, 26 and may protect cancer cells from ferroptosis 27 , SQLE suppression may be an additional mechanism underlying this cancer hallmark. Future work is required to understand the role of squalene accumulation in cancer initiation and progression. In addition, our work identifies cholesterol auxotrophy of ALK + ALCLs as a targetable metabolic liability and adds ALCLs to the small list of cancers that are selectively auxotrophic for a particular nutrient. As a block in LDL uptake inhibits the growth of ALCL tumours in our pre-clinical PDX models, inhibitors of LDLR or approaches that decrease serum cholesterol without increasing tumour LDLR levels might have value in the clinic 28 . Lastly, the workflow we describe can serve as a generalizable approach for identifying additional nutrient dependencies and pro-tumorigenic metabolites across cancer types.
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Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/s41586-019-0945-5. Letter reSeArCH Letter reSeArCH MEthodS Data reporting. No statistical methods were used to predetermine sample size. Cell lines, compounds and constructs. Antibodies to SQLE were purchased from ProteinTech (12544-1-AP, immunoblotting) and Atlas Antibodies (HPA020762, immunohistochemistry). Beta-actin (GTX109639), ACSL4 (GTX100260) and GAPDH (GTX627408) antibodies were obtained from GeneTex; LDL receptor (ab52818), NPC1 (ab36983) and GPX4 (ab41787) antibodies from Abcam; FDFT1 antibody from Protein Tech (13128-1-AP); and ALK (C26G7), STAT3 (9132), phospho-STAT3 (9131) and Histone H3 (4499) antibodies from CST.
Horseradish peroxidase (HRP)-conjugated anti-rabbit antibody was purchased from Santa Cruz; mouse IgG1 isotype control antibody from BioCell; Matrigel from Corning; fetal bovine serum, polybrene, puromycin, squalene and cholesterol from Sigma; blasticidin from Invivogen; LDL from Lee BioSolutions; oleic acid from Santa Cruz; and Dil-LDL, DAPI and BODIPY 581/591 C11 from Thermo Fisher Scientific.
NB-598 Maleate (SQLE inhibitor, SQLEi) was obtained from Adooq Bioscience; ML162 from Aobious; erastin from Tocris; RSL3 from Selleckchem; zaragozic acid A (ZA) from Cayman Chemical; Ferrostatin-1 from Abcam; 4-nitrobenzoate (4-NB) from Alfa Aesar; crizotinib, atorvastatin, 5-azacytidine and 5-Aza-2′deoxycytidine (Decitabine) from Sigma; and Shield-1 from CheminPharma.
Cell culture images were taken with a REVOLVE4 microscope (Echo Laboratories).
All cell lines used in this study were purchased from ATCC and DSMZ or a gift of Sabatini and Weinberg labs. The identities of all the cell lines used in this study were authenticated by single tandem repeat profiling. All the cell lines were routinely tested for mycoplasma contamination every two months. Among all the cell lines, two of them were in ICLAC as misidentified cell lines but included in our analysis for diversity owing to their oncogene status and metabolic phenotypes: U-937 is a rare histiocytic lymphoma cell line described as auxotrophic for cholesterol, and NCI-H929 is a myeloma cell line with low GLUT3 expression.
All cell lines were cultured in RPMI medium (Gibco) containing 1 mM glutamine, 10% fetal bovine serum, penicillin and streptomycin. For proliferation experiments in the absence of serum lipoproteins, regular RPMI was supplemented with 10% fetal bovine lipoprotein deficient serum (LPDS), obtained from Kalen Biomedical. For tracing experiments, [U-13 C]sodium acetate (Cambridge Isotope Laboratories, CLM-156) was used.
For generation of the lentiviral knockout constructs, annealed oligonucleotides (below) were cloned into lentiCRISPR-v2 vector or an inducible DD-Cas9 lentiviral plasmid 29 using a T4 ligase (NEB). sgACSL4_3 forward, 5′-CACCGAA TGACAAGCCAAACCCCAG-3′; sgACSL4_3 reverse, 5′-AAACCTGGGGTT TGGCTTGTCATTC-3′; sgCTRL_1 forward, 5′-CACCGAACGTTGGCACT ACTTCAC-3′; sgCTRL_1 reverse, 5′-AAACGTGAAGTAGTGCCAACGTTC-3′; sgCTRL_2 for ward, 5′-CACCGTCGTGCGCT TCCGGCGGTA-3′; sgCTRL_2 reverse, 5′-AAACTACCGCCGGAAGCGCACGAC-3′; sgCTRL_3 forward, 5′-CACCGTGCCGAGTAATAACGCGAG-3′; sgCTRL_3 reverse, 5′-AAACCTCGCGTTATTACTCGGCAC-3′; sgCTRL_4 forward, 5′-CACCGGTAGGACCTCACGGCGCGC-3′; sgCTRL_4 reverse, 5′-AAAC GCGCGCCGTGAGGTCCTACC-3′; sgCTRL_5 forward, 5′-CACCGCGGATT AGAGGTAATGCGG-3′; sgCTRL_5 reverse, 5′-AAACCCGCATTACCTC TAATCCGC-3′; sgLDLR_2 forward, 5′-CACCGGTGAAGAAGAGGTAG GCGA-3′; sgLDLR_2R, 5′-AAACTCGCCTACCTCTTCTTCACC-3′; sgLDLR_3F, 5′-CACCGCTGCGAGCATGGGGCCCTG-3′; sgLDLR_3 reverse, 5′-AAACCAGGGCCCCATGCTCGCAGC-3′; sgLDLR_4 forward, 5′ -CACCGCCTGGGGCTGGAAAT TGCGC-3′ ; sgLDLR_4 reverse, 5′-AAACGCGCAATTTCCAGCCCCAGGC-3′; sgLDLR_5 for ward, 5′-CACCGTGGCCCAGCGAAGATGCGA-3′; sgLDLR_5 reverse, 5′-AAACTCGCATCTTCGCTGGGCCAC-3′; sgFDFT1_3 forward, 5′ -CACCGGTGCTGGAGGACT TCCCAA-3′ ; sgFDFT1_ 3 reverse, 5′-AAACTTGGGAAGTCCTCCAGCACC-3′; sgFDFT1_5 forward, 5′-CACCGCCGGAGAATGGGCAT TGGGA-3′; sgFDFT1_5 reverse, 5′-AAACTCCCAATGCCCATTCTCCGGC-3′; sgFDFT1_7 forward, 5′-CACCGCGGAAGGTGATGCCCAAGA-3′; sgFDFT1_7 reverse, 5′-AAACTCTTGGGCATCACCTTCCGC-3′; sgFDFT1_8 forward, 5′ -CACCGT TCATGGAGAGCAAGGAGA-3′ ; sgFDFT1_ 8 reverse, 5′-AAACTCTCCTTGCTCTCCATGAAC-3′; sgFDFT1_10 forward, 5′ -CACCGACTATCTGGAAGACCAGCA-3′ ; sgFDFT1_10 reverse, 5′-AAACTGCTGGTCTTCCAGATAGTC-3′; sgAAVS1 forward, 5′-CACCGGGGCCACTAGGGACAGGAT-3′; sgAAVS1 reverse, 5′ -AAACATCCTGTCCCTAGTGGCCCC-3′; sgSQLE_5 for ward, 5′ -CACCGCAGCTGTGCT T TCCAGAGA-3′ ; sgSQLE_5 reverse, 5′-AAACTCTCTGGAAAGCACAGCTGC-3′.
SQLE cDNA and sgRNA-resistant FDFT1 cDNA were synthesized as gBlock (IDT) and cloned into PMXS-IRES-Blast vector by Gibson assembly. HSD17B7 was cloned using the following primers: HSD17B7 forward, 5′-ATGGATCCGCCACCATGCGAAAGGTGGTTTTGATCACCGG-3′; HSD1 7B7 reverse, 5′-ATGCGGCCGCTTATAGGCATGAGCCACTGAGCCTGG-3′.
Cloning of oncogenic NPM-ALK into PMXS-IRES-Blast by Gibson assembly was achieved by PCR of wild-type NPM-ALK (NPM is also known as NPM1) or its dead kinase version from previously generated constructs 30 using the following prime rs: NPM-ALK forward, 5′-GCCGGATCTAGCTAGTTAATTAAGCCACCG CCACCATGGAAGATTCGATGGACATGG-3′; NPM-ALK reverse, 5′-GGGC GGAATTTACGTAGCTCAGGGCCCAGGCTGGTTCATG-3′. Proliferation assays. Cell lines were cultured in 96-well plates at 5,000 cells per well in a final volume of 0.2 ml RPMI-1640 medium (Gibco) with the indicated treatments. After 5 days of growth, 40 μl of Cell Titer Glo reagent (Promega) was added and luminescence was read using a SpectraMax M3 plate reader (Molecular Devices). Data are presented as relative fold change in luminescence to that of untreated cells. For proliferation assays under lipoprotein depletion, RPMI medium was supplemented with 10% LPDS and luminescence was read after 6 days of growth. Data are presented as relative fold change in luminescence to that of cells grown in LPDS medium supplemented with 100 μg ml −1 LDL. In cholesterol rescue experiments, 100 μg ml −1 LDL (corresponding to total 50 μg ml −1 of cholesterol) or 10 μg ml −1 free cholesterol were used, as higher free cholesterol levels impair viability of cell lines.
Of note, in our proliferation assays, we observed that glutamine levels-which correlate with the freshness of the culture medium-affect the dose of ML162 required to reduce cell proliferation and viability. Real-time PCR assays. RNA was isolated by a RNeasy Kit (Qiagen) according to the manufacturer's protocol. RNA was spectrophotometrically quantified and equal amounts were used for cDNA synthesis with the Superscript II RT Kit (Invitrogen). qPCR analysis was performed on an ABI Real Time PCR System (Applied Biosystems) with the SYBR green Mastermix (Applied Biosystems). The primers used are: human SQLE forward, 5′-TCCTTGCTCAGGCTCTTTATG-3′; human SQLE reverse, 5′-AGGGTTAGGAGACAATACAGAAAG-3′; HSD17B7 forward, 5′-GACCTTTTGAGTGTGGCTTTG-3′; HSD17B7 reverse, 5′-ACGGA GGCAGAATTCCATATG-3′; RPLO forward, 5′-CCTCTTTCCCTTCG GTGTG-3′; RPL0 reverse, 5′-AATCTTGGCATCAGGGACAC-3′; NPM forward, 5′-GGGCCAGTGCATATTAGTGGA-3′; ALK reverse, 5′-TGTACTCAGGGCTCT GCAGCT-3′; human β-actin forward, 5′-TTTTGGCTATACCCTACTGGCA-3′; human β-actin reverse, 5′-CTGCACAGTCGTCAGCATATC-3′; mouse SQLE forward, 5′-CCCAAAACACAAAATCCTCAG-3′; mouse SQLE reverse, 5′-GCAA TGCCAAGAAAAGTCCAC-3′; mouse β-actin forward, 5′-GTTGTGAATGT ATTGGCTCAGG-3′; mouse β-actin reverse, 5′-AATATTGAAAGCAA CCCAACAGG-3′. Results were normalized to RPL0 or β-actin. Dil-LDL uptake. Cells were washed twice in HBSS (Gibco) and resuspended (250,000 cells per replicate) in 0.5 ml of LPDS medium supplemented with 5 μg ml −1 of Dil-LDL. To measure non-specific emission, one control well was used by adding 5 μg ml −1 of non-fluorescent unlabelled LDL. Cells were incubated at 37 °C for 6 h before collection in 1.5 ml tubes and two consecutive washes with HBSS. Cells were then lysed with 100 μl of radioimmunoprecipitation assay (RIPA) buffer and spun down for 5 min at 20,000g. Fifty microlitres of the supernatants was transferred to a 96-well plate (Greiner) and fluorescence was measured with a SpectraMax M3 plate reader at an excitation wavelength of 520 nm and an emission wavelength of 580 nm. Dil-LDL uptake is shown as the specific Dil-LDL emission at 580 nm per μg of protein.
Generation of knockout and cDNA overexpression cell lines.
For inducible knockout experiments, sgRNAs targeting LDLR (5′-GCTGCG AGCATGGGGCCCTG-3′), ACSL4 (5′-GAATGACAAGCCAAACCCCAG-3′) or a control sgRNA (AAVS1, 5′-GGGGCCACTAGGGACAGGAT-3′) were cloned into lentiviral DD-Cas9 vector. This vector was transfected into HEK293T cells with lentiviral packaging vectors VSV-G and Delta-VPR using XtremeGene transfection reagent (Roche). For transduction, indicated cells were spininfected in 6-well tissue culture plates using 8 μg ml −1 of polybrene at 1,200g for 1.5 h and selected by puromycin before addition of 250 nM Shield-1 reagent for 3 days. The knockout of the target gene was verified by immunoblotting. For generation of FDFT1-knockout cells or SQLE-knockout cells, an sgRNA targeting FDFT1 (5′-GCCGGAGAATGGGCATTGGGA-3′) or SQLE (5′-GCAGCTGTGCTTTCCAGAGA-3′) was cloned into lentiCRISPR-v2. After transduction and selection using puromycin, cells were single-cell cloned. For overexpression of SQLE, guide-resistant version of FDFT1, NPM-ALK or its dead kinase version, retroviral vectors with indicated cDNAs were transfected with retroviral packaging plasmids Gag-pol and VSV-G into HEK293T cells. After transduction, cells were selected with blasticidin. Metabolite profiling and isotope tracing. For lipid metabolite profiling experiments, each indicated cell line (1 × 10 6 cells per replicate) was cultured as triplicates in 6-well plates and treated for 24 h with ML162 (200 nM), Fer-1 (1 μM), ZA (20 uM), 4-NB (1 mM) or atorvastatin (1 uM) before collection of cells and two consecutive washes with 1 ml of cold 0.9% NaCl. To measure squalene synthesis, SNU-1 cells were seeded in 60 mm dishes at 70% confluency. After 24 h, cells were given fresh medium with [U-13 C]sodium acetate (10 mM). Cell pellets were resuspended in 600 μl of cold LC/MS grade methanol, and non-polar metabolites extracted by consecutive addition of 300 μl LC/MS grade water followed by 400 μl of LC/MS grade chloroform. After 10 min extraction by vortexing and centrifugation for 10 min at 10,000g and 4 °C, the lower lipid-containing layer was carefully collected and dried under nitrogen. Dried lipid extracts were stored at −80 °C until LC/MS analysis.
Lipids were separated on an Ascentis Express C18 2.1 mm × 150 mm × 2.7 μm column (Sigma-Aldrich) connected to a Dionex UlitMate 3000 UPLC system and a QExactive benchtop orbitrap mass spectrometer (Thermo Fisher Scientific) equipped with a heated electrospray ionization (HESI) probe. Dried lipid extracts were reconstituted in 50 μl 65:30:5 acetonitril:isopropanol:water (v/v/v) and 5 μl of sample were injected into the LC/MS/MS, with separate injections for positive and negative ionization modes. Mobile phase A in the chromatographic method consisted of 60:40 water:acetonitrile with 10 mM ammonium formate and 0.1% formic acid, and mobile phase B consisted of 90:10 isopropanol:acetonitrile, with 10 mM ammonium formate and 0.1% formic acid. The chromatographic gradient has previously been described 31 . The column oven and autosampler were held at 55 °C and 4 °C, respectively. The mass spectrometer parameters have previously been described 32 . The spray voltage was set to 4.2 kV, and the heated capillary and the HESI were held at 320 °C and 300 °C, respectively. The S-lens RF level was set to 50, and the sheath and auxiliary gas were set to 35 and 3 units, respectively. These conditions were held constant for both positive and negative ionization mode acquisitions. External mass calibration was performed every seven days using the standard calibration mixture.
Mass spectra were acquired in both full-scan and data-dependent MS/MS mode. For the full-scan acquisition, the resolution was set to 70,000, the AGC target was 1 × 10 6 , the maximum injection time was 50 ms, and the scan range was m/z = 133.4 − 2,000. For data-dependent MS/MS, the top 10 ions in each full scan were isolated with a 1.0 Da window, fragmented with a step-wise collision energy of 15, 25 and 35 units, and analysed at a resolution of 17,500 with an AGC target of 2 × 10 5 and a maximum injection time of 100 ms. The underfill ratio was set to 0. The selection of the top 10 ions was set to isotopic exclusion, a dynamic exclusion window of 5.0 s, and an exclusion list of background ions based on a solvent bank.
High-throughput identification and relative quantification of lipids was performed separately for positive and negative ionization mode data, using LipidSearch software (Thermo Fisher Scientific/Mitsui Knowledge Industries) 33, 34 and the default parameters for QExactive product search and alignment. After alignment, raw peak areas for all identified lipids were exported to Microsoft Excel and filtered according to the following predetermined quality control criteria: Rej ('Reject' parameter calculated by LipidSearch) equal to 0; PQ ('Peak Quality' parameter calculated by LipidSearch software) greater than 0.85; CV (standard deviation/mean peak area across triplicate injections of a represented (pooled) biological sample) below 0.4; R (linear correlation across a three-point dilution series of the representative (pooled) biological sample) greater than 0.9. Typically, approximately 70% of identified lipids passed all four quality control criteria. Raw peak areas of the filtered lipids were added together to create a total lipid signal for each sample, and individual lipid peak areas were normalized to this total signal as a control for lipid extraction and efficiency, as well as sample loading. Of note, in the total lipid quantification of FDFT1 knockout Karpas299 cells compared to rescued control, we observed an enrichment of membrane phospholipids containing saturated fatty acids (Extended Data Fig. 7c ), probably due to the fact that these species are more resistant to oxidative stress and may replace or be enriched in membrane lipids upon oxidative stress.
To measure cholesterol, lanosterol, squalene and CoQ10, a XCalibur QuanBrowser 2.2 (Thermo Fisher Scientific) was used a 5-ppm mass tolerance and referenced an in-house library of chemical standards. Total lipid signal calculated with LipidSearch was used to normalize raw peak areas to generate relative abundance. Immunoblotting. Cell pellets were washed twice with ice-cold PBS before lysis in lysis buffer (10 mM Tris-Cl pH 7.5, 150 NaCl, 1 mM EDTA, 1% Triton X-100, 2% SDS, CHAPS 0.1%) supplemented with protease inhibitors and PhosSTOP (Roche). Each cell lysate was sonicated and, after centrifugation for 10 min at 4 °C and 20,000 g, supernatants were collected and their protein concentration determined by a Pierce BCA Protein Assay Kit (Thermo Scientific) with bovine serum albumin as a protein standard. Samples were resolved on 8% or 12% SDS-PAGE gels and analysed by immunoblotting as previously described 35 . Targeted bisulfite sequencing. Assays were designed targeting CpG sites in SQLE promoter region using primers created with Rosefinch. All primers were resuspended in TE solution at 100 μM and validated using 1 ng of bisulfite-converted control DNA. Following primer validation, samples were bisulfite converted using the EZ DNA Methylation-Lightning Kit (Zymo D5030) according to the manufacturer's instructions. Multiplex amplification of all samples with specific primer pairs and the Fluidigm Access Array System was performed according to the manufacturer's instructions. The resulting amplicons were pooled for collection and subsequent barcoding according to the Fluidigm instrument's guidelines. After barcoding, samples were purified by a ZR-96 DNA Clean & Concentrator (Zymo D4023) and then prepared for massively parallel sequencing using a MiSeq V2 300 bp Reagent Kit and paired-end sequencing protocol according to the manufacturer's guidelines.
Sequence reads were identified by a standard Illumina base-calling software and then analysed by a Zymo Research proprietary analysis pipeline, which is written in Python. Low-quality nucleotides and adaptor sequences were trimmed off during analysis quality control. Sequence reads were aligned back to the reference genome using Bismark, an aligner optimized for bisulfite sequence data and methylation calling 36 . Paired-end alignment was used as default thus requiring both read 1 and read 2 be aligned within a certain distance, otherwise both read 1 and read 2 were discarded. Index files were constructed using the 'bismark_genome_preparation' command and the entire reference genome. The '-non_directional' parameter was applied while running Bismark. All other parameters were set to default. Nucleotides in primers were trimmed off from amplicons during methylation calling. The methylation level of each sampled cytosine was estimated as the number of reads reporting a C, divided by the total number of reads reporting a C or T. DNA barcode cell mixing. DNA barcode cell competition assay was performed as previously described using the same primer and barcoding sequences 35 ( Supplementary Table 1 ). In brief, a unique 7-bp sequence was transduced into 28 different cancer cell lines using lentiviruses produced from a PLKO.1P vector. Each cell line was infected with three barcodes in separate infections for statistical analysis. To perform cell competition assays, barcoded cell lines were mixed in equal amounts and the mixed population was cultured under indicated conditions for 15 days. Cells were then collected for genomic DNA and processed for Illumina deep sequencing. Barcode abundance was determined in the starting population and after the growth. CRISPR-based screen. The highly focused metabolism sgRNA library was designed as previously described by including representation of key genes of every mammalian metabolic pathway ( Supplementary Table 3 ). Oligonucleotides for sgRNAs were synthesized by Integrated DNA Technologies and annealed before they were introduced in lentiCRISPR-v2 vector using a T4 DNA ligase kit (NEB), following manufacturer's instructions. Ligation products were then transformed in NEB stable competent E. coli (NEB) and the resulting colonies were grown overnight at 32 °C and plasmids isolated by Miniprep (QIAGEN). This plasmid pool was used to generate a lentiviral library containing five sgRNAs per gene target. This viral supernatant was titred in each cell line by infecting target cells at increasing amounts of virus in the presence of polybrene (8 μg ml −1 ) and by determination of cell survival after 3 days of selection with puromycin. Two million of each cell type were infected at a MOI of 1 before selection with puromycin for 3 days. An initial pool of two million cells was collected. Infected cells were then cultured for 14 population doublings, after which two million cells were collected and their genomic DNA extracted by a DNeasy Blood & Tissue kit (QIAGEN). For amplification of sgRNA inserts, we performed PCR using specific primers for each condition. PCR amplicons were then purified and sequenced on a NextSeq 500 (Illumina). Sequencing reads were mapped and the abundance of each sgRNA was measured. Gene score is defined as the median log 2 fold change in the abundance between the initial and final population of all sgRNAs targeting a particular gene. Immunohistochemistry. Immunohistochemistry staining was performed as previously described 12 . SQLE protein expression was evaluated in primary and patient-derived tumour xenograft ALCL formalin-fixed tissues samples using a rabbit polyclonal anti-human SQLE (Atlas Antibodies, 1:200). LDLR monoclonal antibody purification. Hybridoma cell lines producing a monoclonal antibody against LDLR have previously been described 37 . These cell lines were cultured in RPMI supplemented with 20% FBS and 2 mM pyruvate. LDLR antibody was then purified using a Protein G resin (GenScript) and Protein G Sepharose 4 Fast Flow (GE Healthcare) following the manufacturer's instructions. C11-BODIPY lipid peroxidation. Cells were plated (250,000 cells per well) in six-well plates and treated with ML162 for 18 h before two washes with HBSS and incubation of cells in 500 μl of HBSS containing BODIPY 581/591 C11 (1 μM). After 15 min incubation at 37 °C, cells were washed twice on ice-cold HBSS and resuspended in 0.5 ml of HBSS containing 50 ng ml −1 DAPI and filtered into FACS tubes with cell-strainer cap (Falcon). Flow cytometry data were collected on a BD LSR II Flow Cytometer (BD Biosciences) by using an excitation wavelength of 488 nm and the FL1 collection channel. FlowJo v.10 software was used for data analysis. Live cells were selected from the starting cell population on a DAPI/ FSC-A plot. Then, single cells were selected using a FSC-A/FSC-H plot from the population of live cells. Data represents populations of live singlet cells. Spontaneous Raman spectroscopy and SRS microscopy. Spontaneous Raman spectra were acquired by a confocal Raman microspectroscopy (Xplora; HORIBA Jobin Yvon) equipped with a 532-nm (40-mW) laser and a 100× objective (air, N.A. = 0.9, MPlan N; Olympus). Spectra of pure squalene and cholesterol were acquired with 5 s integration. Cell spectra were obtained from the lipid droplets (identified under bright field) of cells fixed with 4% paraformaldehyde after 120-s integration. Glass and solution background was subtracted by measuring signal from adjacent area.
Chemical imaging by SRS microscopy was acquired on an integrated inversed confocal laser-scanning microscope (FV1200; Olympus) equipped with a water-immersion 25× objective (1.05 N.A. XLPLNXWMP2; Olympus). Concentration mapping of selected chemical bond vibration was achieved by raster-scanning two spatially and temporally overlapped picosecond laser beams (picoEmerald, Applied Physics and Electronics) across the sample. SRS signal was generated when the frequency difference of the two beams (pump, tunable; Stokes, 1,064 nm) matched the vibrational frequency, and was subsequently extracted through high-frequency modulation transfer scheme. Specifically, the Stokes beam was modulated by an electro-optic modulator at 8MHz. Transmitted light was collected by an oil-immersion condenser (1.4 N.A.; Olympus) and filtered by a bandpass filter (890/220 CARS; Chroma Technology), so that only pump beam was detected by a Si photodiode (FDS1010; Thorlabs, biased at 64V). The terminated signal was then pre-filtered (8MHz ± 1MHz, KR 2724; KR electronics), and then demodulated by a lock-in amplifier (SR844; Stanford Research Systems). Laser powers on sample were measured to be 120 mW (Stokes) and 100 mW (pump). Images were acquired at a speed of 100 s per pixel by Fluoview Software.
Images at three channels were obtained for each cell. The corresponding wavelengths of pump were: 928.4 nm (1,372 cm −1 ), 927.2 nm (1,386 cm −1 ), 926.0 nm (1,400 cm −1 ). Among these, 1,386 cm −1 is the squalene on-resonance frequency (vibrational peak), whereas 1,372 cm −1 and 1,400 cm −1 are the squalene off-resonance frequencies (baseline of cell mass). Thus, the image of squalene distribution is calculated as
in which I represents SRS intensity from each channel. Images were calculated (in unit of demodulated terminated photocurrent) and later assigned pseudo-colours in ImageJ. SRS signal is proportional to concentration and it is limited by laser shot noise, thus the detection limit is usually submillimolar to millimolar 38 . Squalene accumulates at these high concentrations in lipid droplets, and may still be present in other subcellular compartments and membranes at lower concentrations, but remains undetected by SRS microscopy. Gene correlation of primary ALCLs and cancer cell lines. RNA-sequencing data was obtained from a previously published work with SRA accession number SRA176318 12 . Differentially expressed transcripts were identified using the R package limma. False discovery rate was used to correct for multiple hypothesis testing with a significance threshold of 0.01. The identification of most differentially expressed genes was performed using Student's t-test statistic (Supplementary Table 2 ). Microarray expression data of SQLE was obtained from Cancer Cell Line Encyclopedia 39 . Generation of patient-derived tumour xenografts. PDX models were generated as previously described 12, 40 . In brief, tumour graft samples were cut into multiple 3 × 3 × 1-mm pieces (multiple pieces per specimen) in complete medium and implanted fresh and/or cryopreserved in 10% DMSO-RPMI-1640 frozen medium supplemented with 20% FCS. Six-to-eight-week-old NOD.Cg B2m tm1Unc Prkdc scid Il2rg tm1Wjl /SzJ mice (NSG) were first anaesthetized (Rompun 0.05 μl g −1 Zoletil 1.6 μg g −1 i.m.). Then, with animals lying on their ventral site, the dorsal region was sterilized (70% ethanol). Multiple tumour-graft tissue fragments (2) (3) (4) were subcutaneously injected using a trocar. Implant growth was assessed by palpation and or by MRI scanning and collected when tumour masses were required. Tumour volumes were assessed using an electronic caliper. Recipient animals were checked regularly and killed at early sign of distress. At collection, mice were killed in a CO 2 chamber and grafts were collected for histologic evaluation, re-grafting, or snap-freezing in liquid nitrogen. Tumours were then dissociated to single cells using a phosphate buffer containing Collagenase A (25,000 U ml −1 ), Dispase II (12.5 U ml −1 ), DNase (500 U ml −1 ). Cells were then filtered through a 100-μm filter and washed twice in PBS. After an overnight culture in RPMI (Lonza), floating live cells were selected with a ficoll (Ficoll-Paque-Plus, GE Healthcare). Multi-colour flow cytometry was used to check the percentage of the neoplastic T cells.
Fresh and/or viable cryopreserved samples were obtained at the time of diagnosis, prior treatment or at relapse after single or multiple chemotherapy protocols. Informed consent was obtained following the procedures approved by the Weill Cornell and Memorial Sloan Cancer Center ethical committees. Diagnoses were assigned according to the WHO classification by at least two experienced pathologists. Samples IL69 and IL79 (ALK + PDX1 and ALK + PDX3 in Fig. 3h ) correspond to patients who experienced a refractory clinical course unresponsive to standard chemo-immunotherapy. Patient IL69 corresponds to a 20-year-old male patient diagnosed with ALK + ALCL and received two cycles of CHOP followed by two additional three cycles of BV-CHP. On progressive disease, the patient was treated with Crizotinib but he died with active systemic disease and CNS involvement after a month. IL79 was a 65-year-old male patient with a relapsed ALK + ALCL treated with BV-CHOP versus CHOP, who also died with progressive disease after four months of therapy ( Supplementary Table 5 ). Mini competition assay. Five control sgRNAs targeting intergenic regions, four sgRNAs targeting LDLR, and five sgRNAs targeting FDFT1 were cloned into linearized lentiCRISPR-v2 vector and transformed in NEB competent E. coli. Each plasmid was then pooled at equal concentrations and used for lentivirus production as previously described. DEL cell line was infected and selected with puromycin for three days before being in vitro cultured or injected subcutaneously in NSG mice. Similarly, collagenase-digested ALCL PDX cells were transduced with the same lentiviral particles and subsequently injected subcutaneously in immunodeficient mice 24 h after infection. No antibiotic selection was performed as these cells cannot grow under standard culture conditions. Tumours were collected after 2-4 weeks of growth. An initial pool of each sample was taken for normalization. After 14-21 days guide DNAs were isolated and amplified by PCR. PCR amplicons were then sequenced on a NextSeq 500 (Illumina). Guide scores were calculated as median log 2 fold change in the abundance between the initial and final population of that sgRNA similar to standard CRISPR screens. Mouse studies. All animal studies and procedures were conducted according to a protocol approved by the Institutional Animal Care and Use Committee (IACUC) at the Rockefeller University. All mice were maintained on a standard light-dark cycle with food and water ad libitum. For in vivo LDLR experiments, xenograft tumours were initiated by injecting 1 × 10 6 cells per 100 ul PBS of ALCL or control cell lines subcutaneously. For ALCL cells coming from PDXs, injections contained 1 × 10 6 cells per 100 ul 30% Matrigel. After injections in the left and right flanks of male and female 6-14-week-old NOD scid gamma (NSG) mice (Taconic), tumours were grown for 2-4 weeks. For patient-derived tumour xenograft models, NSG B2m and NSG mice were handled according to Weill Cornell Medical Institute's Institutional Animal Care and Use Committee-approved protocol 2014-0024. All operatively resected tumours were collected after written patient consent and in accordance with the institutional review board approved protocols of Weill Cornell Medical Institute (2014-0024, 0201005295R012, 1410015560A002 and 0107004999).
For tumour experiments with FDFT1-knockout and SQLE-expressing Karpas299 cell lines, 5-10 × 10 4 cells per 100 ul PBS of each cell line were injected subcutaneously into NSG mice and grown for 28 days. Injection of higher number of cells resulted in a loss of significance in tumour size difference, a result that is consistent with previously published work 26 .
In no cases did xenograft tumour size surpassed the limit permitted by our protocol (2 cm). All treatment studies were randomized and injections were performed by blinded investigators. Statistics and reproducibility. GraphPad PRISM 7 and Microsoft Excel 15.21.1 software were used for statistical analysis. All experiments were performed at least two times with similar results. Both technical and biological replicates were reliably reproduced. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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Sample size
All the experiments were performed using sample sizes based on standard protocols in the field. For primary tumor samples and Patient Derived Tumor Xenografts (PDTXs), sample size depended on the availability of patient samples for each cancer subset as provided by our collaborator.
Data exclusions No data was excluded in any case.
Replication
All the in vitro experiments were replicated with similar outcome at least 3 times. Both technical and biological replicates were reliably reproduced.
In vivo experiments were reproduced at least twice.
Randomization Sample groups were allocated randomly.
Blinding
The investigator(s) were not blinded during data collection or analysis. For in vivo experiments, blinded researchers performed the injections.
Reporting for specific materials, systems and methods 
Antibodies
Antibodies used chemo-immunotherapy. IL69 correspond to a 20-year-old male diagnosed with ALK+ ALCL of the right shoulder, who received 2 cycle of CHOP followed by two additional 3 cycles of BV-CHP. On progressive disease, the patient was treated with Crizotinib but he died with active systemic disease and CNS involvement after a month. IL79 was a 65-year-old male with a relapsed ALK+ ALCL treated with BV-CHOP vs CHOP, who also died with progressive disease after 4 month of therapy (Supplementary Table 5 ). Fresh and/or viable cryopreserved samples from primary ALCL were obtained at the time of diagnosis, before treatment, or at relapse after chemotherapy. Formalin Fixed Paraffin Embedded tissue samples were obtained from multiple institutions and the diagnoses were rendered according to the WHO classification. Review of samples were performed in blind by two experienced pathologists to determine the percentage of lymphoma cells, based on H&E and immunohistochemistry (CD30 etc.). Only samples with more than 50% of tumor cells were selected for further analyses. Representative formalin-fixed tumor sections and/or tissue microarrays (TMAs) were processed for immunohistochemical (IHC) analyses on a semi-automated stained. Informed consents were obtained following the recommendations of local ethical committees.
Recruitment
See above.
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Methodology Sample preparation
Indicated cancer cell lines were plated (250,000 cells/well) in 6-well plates and treated with ML162 for 18 hrs prior to two washes with HBSS and incubation of cells in 500 uL of HBSS containing BODIPY 581/591 C11 (1 uM). After 15 min incubation at 37 °C, cells were washed twice on ice-cold HBSS and resuspended in 0.5 mL of HBSS containing 50ng/ml DAPI and filtered into FACS tubes with cell-strainer cap.
Instrument BD LSR II Flow Cytometer (BD Biosciences)
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FlowJo v.10
